Navigation Links
Going Straight to Chemo May Be Better for Certain Breast Cancers
Date:9/6/2011

TUESDAY, Sept. 6 (HealthDay News) -- Breast cancer patients with the BRCA1 gene mutation have a much better response to neoadjuvant chemotherapy -- chemo given before other treatment -- than other breast cancer patients, a new study finds.

U.S. researchers looked at 317 patients with different stages of breast cancer who underwent neoadjuvant chemotherapy.

Complete pathological response (pCR) -- the disappearance of all evidence of cancer from the breast tissue and lymph nodes -- occurred in 46 percent of those with the BRCA1 mutation, 13 percent of those with the BRCA2 mutation, and 22 percent of patients with neither mutation, the study authors found.

BRCA1 carriers who achieved a pCR after neoadjuvant chemotherapy also had a better five-year, relapse-free survival and overall survival rates, although the latter difference was not statistically significant, said the University of Texas M.D. Anderson Cancer Center researchers.

After neoadjuvant chemotherapy, 61 patients had breast-conserving surgery and 256 underwent mastectomy.

"While hereditary breast cancers typically carry aggressive tumor features compared to sporadic [non-inherited] breast cancers, we found that BRCA1-related tumors were as responsive and sensitive to anthracycline and taxane-based chemotherapy as were sporadic breast cancers," lead author Dr. Banu Arun, a professor in the department of breast medical oncology, said in an M.D. Anderson news release. "These findings may help physicians determine the best treatment method for this subset of women with unique genetic mutations."

The study is published in the Sept. 6 online edition of the Journal of Clinical Oncology.

A lack of prospective studies means there is no consensus on the most effective chemotherapy regimen for breast cancer patients with a BRCA1 mutation, according to Arun.

"This new insight tempts us to speculate that the presence of the BRCA1 mutation determines how some women will respond to neoadjuvant chemotherapy. However, we need future prospective studies with larger cohorts and longer-term follow up to validate these findings and determine optimum treatment," Arun said in the news release.

More information

The U.S. National Cancer Institute explains adjuvant and neoadjuvant therapy for breast cancer.

-- Robert Preidt

SOURCE: University of Texas M.D. Anderson Cancer Center, news release, Sept. 6, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Going Full-Tilt Into Turns May Ease Motion Sickness on Trains
2. Afghan Medical Staff Face Ongoing Security Threats: Study
3. More People May Benefit From Going Gluten-Free
4. Childhood cancer survivors are at increased risk for ongoing post-therapy GI complications
5. Ongoing relationship with care provider key for patients with a chronic condition: UBC study
6. Researchers find many elderly men are undergoing unnecessary PSA screenings
7. Negative attitudes toward fat bodies going global, study finds
8. Going Green May Cut Hospital Costs
9. Many Higher-Income Parents Forgoing Kids Vaccinations: Report
10. Younger Men Not Going to the Doctor Enough, Survey Shows
11. Studies identify complications in women undergoing mastectomy and immediate breast reconstruction
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Going Straight to Chemo May Be  Better for Certain Breast Cancers 
(Date:7/25/2017)... ... July 25, 2017 , ... ... it will be exhibiting and providing demos of its smart journaling platform at ... Convention Center in Washington D.C. from August 3-6, 2017. , The APA Annual ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus ... United States, today announced its partnership with financial technology company, Automated Transaction Delivery ... of the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated ...
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn boy this ... of a new benefit for employees that is uncommon in American business: 12 weeks ... supports me and other employees as new parents. It keeps our family life more ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
(Date:7/24/2017)... JACKSONVILLE, Florida (PRWEB) , ... ... ... Klaproth, Division Marketing Director,      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins ... guests joined together to celebrate the structural topping out of the new ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), today announced that it has reached ... holder and largest shareholder, to modify its existing credit ... to the modification, WAVI agreed to exchange its existing ...
Breaking Medicine Technology: